All In Biotech

Free tool

FAERS Monitor: Retacrit

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125545 or its brand name (Retacrit, Epoetin Alfa-Epbx). Reports on generic versions are filed under their own applications.

Reports

2,244

Serious

1,516

68% of reports

Hospitalization

679

Death reported

494

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death416
  • off label use329
  • haemoglobin decreased167
  • anaemia109
  • asthenia85
  • diarrhoea80
  • fatigue78
  • hospitalisation73
  • product dose omission issue61
  • nausea58
  • pneumonia58
  • malaise54
  • drug ineffective52
  • dyspnoea48
  • acute kidney injury45

Reports by year received

View as table
YearReports
20081
20092
20104
20117
20128
201314
201413
20162
20176
201839
2019151
2020349
2021327
2022381
2023402
2024199
2025166
2026173

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,915 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemoglobin decreasedSignal16715.313.22,220
anaemiaSignal1095.44.5385
deathSignal4164.54.21,188
hospitalisationSignal734.53.6193
off label useSignal3293.53.2617
acute kidney injurySignal452.82.149
astheniaSignal852.11.750
product dose omission issue611.91.527
pneumonia581.71.315
diarrhoea801.20.92
malaise541.20.91
fatigue780.90.80
dyspnoea480.80.62
nausea580.70.58
drug ineffective520.40.359

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.